JELIS is irrelevant right now because FDA is clear on that the Statin used in the trial was suboptimal, even though I think most people would still take suboptimal Statin due to side effects.
Genzyme-developed MS drug potentially risky, according to FDA staff report, Until Friday, approval from the Food and Drug Administration seemed likely, especially since European regulators in September signed off on its sale overseas.
Immunogen's response will be the key here. If they keep quiet, there will be more doubt in their technology. The share price will take hit every day.
where possibly to find the original data?
Is the price of $184 weekly or monthly? I thought it was for monthly, $6/day. If it is for weekly, it would have been $25/day
When we will be able to see some Inspire result? It stared just under one year later than START. The patients would have lived longer. However, only 400 patients were to be enrolled. Now the requirements have been changed to concurrent radio-chemo therapy, the result should be more convincing even though it may not be stat significant.
Great find. This is truely remarkable. The final outcome could be any time based the rate from 44% to 75%.